Rapport Therapeutics, Inc. S-3ASR, filed Mar 10, 2026: EX-FILING FEES
| Calculation of Filing Fee Tables | |||
| S-3 | |||
| Rapport Therapeutics, Inc. | |||
| Table 1: Newly Registered and Carry Forward Securities |
|---|
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
Carry Forward Form Type |
Carry Forward File Number |
Carry Forward Initial Effective Date |
Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Newly Registered Securities | |||||||||||||
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.001 per share | 457(r) | 0.0001381 | ||||||||
| Fees to be Paid | 2 | Equity | Preferred Stock, par value $0.001 per share | 457(r) | 0.0001381 | ||||||||
| Fees to be Paid | 3 | Debt | Debt Securities | 457(r) | 0.0001381 | ||||||||
| Fees to be Paid | 4 | Equity | Warrants | 457(r) | 0.0001381 | ||||||||
| Fees to be Paid | 5 | Equity | Units | 457(r) | 0.0001381 | ||||||||
| Fees to be Paid | 6 | Equity | Common Stock, par value $0.001 per share | 457(o) | 150,000,000 | $ 150,000,000.00 | 0.0001381 | $ 20,715.00 | |||||
| Fees Previously Paid | |||||||||||||
| Carry Forward Securities | |||||||||||||
| Carry Forward Securities | |||||||||||||
| Total Offering Amounts: |
$ 150,000,000.00 |
$ 20,715.00 |
|||||||||||
| Total Fees Previously Paid: |
$ 0.00 |
||||||||||||
| Total Fee Offsets: |
$ 17,223.75 |
||||||||||||
| Net Fee Due: |
$ 3,491.25 |
||||||||||||
| Offering Note |
| 1 |
(1a)The amount to be registered consists of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of debt securities, common stock, preferred stock or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-3ASR (this "Registration Statement") also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. (1b) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. (1c) Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be. (1d) In accordance with Rules 456(b) and 457(r) under the Securities Act, except with respect to any registration fee associated with the primary offering of common stock described in the table in connection with the filing of this Registration Statement, the registrant is deferring payment of all registration fees and will pay the registration fees subsequently in advance or on a "pay-as-you-go" basis. | ||||||
| | |||||||
| 2 |
See Note 1a, Note 1b, Note 1d. (2a) Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be. | ||||||
| | |||||||
| 3 |
See Note 1a, Note 1b, Note 1d. (3a) Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be. | ||||||
| | |||||||
| 4 |
See Note 1a, Note 1b, Note 1d. (4a) Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock, preferred stock, debt securities, or units registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required. | ||||||
| | |||||||
| 5 |
See Note 1a, Note 1b, Note 1d. (5a) Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this Registration Statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required. | ||||||
| | |||||||
| 6 |
See Note 1a, Note 1b, Note 1d. | ||||||
| | |||||||
| Table 2: Fee Offset Claims and Sources |
|---|
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rules 457(b) and 0-11(a)(2) | |||||||||||||
| Fee Offset Claims | |||||||||||||
| Fee Offset Sources | |||||||||||||
| Rule 457(p) | |||||||||||||
| Fee Offset Claims | 1 | Rapport Therapeutics, Inc. | S-3 | 333-288444 | 07/01/2025 | $ 17,223.75 | Unallocated (Universal) Shelf | Unallocated (Universal) Shelf | 112,500,008 | $ 112,500,008.00 | |||
| Fee Offset Sources | 2 | Rapport Therapeutics, Inc. | S-3 | 333-288444 | 07/01/2025 | $ 61,240.00 | |||||||
| Rule 457(p) Statement of Withdrawal, Termination, or Completion: |
| 1 |
(1a) The registrant previously registered $400,000,000 of an indeterminate amount of securities to be offered from time to time at prices to be determined at the time of each such offering pursuant to a Registration Statement on Form S-3 (File No. 333-288444) filed with the Securities and Exchange Commission (the "Commission") on July 1, 2025, and declared effective by the Commission on July 9, 2025 (the "Prior Registration Statement"). The registrant previously paid an aggregate registration fee of $61,240.00 in connection with the Prior Registration Statement (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement). As of the date of filing of this Registration Statement, the registrant sold an aggregate of $287,499,992.00 of such securities under the Prior Registration Statement, leaving the balance of $112,500,008.00 (the "Unsold Securities"), representing $17,223.75 in registration fees, of such Unsold Securities under the Prior Registration Statement. Pursuant to Rule 457(p) under the Securities Act, such unutilized filing fees may be applied to the filing fees payable pursuant to this Registration Statement. | ||||||
| | |||||||
| Offset Note |
| 2 |
See note 1a. | ||||||
| | |||||||
| Table 3: Combined Prospectuses |
|---|
| Security Type |
Security Class Title |
Amount of Securities Previously Registered |
Maximum Aggregate Offering Price of Securities Previously Registered |
Form Type |
File Number |
Initial Effective Date | |
|---|---|---|---|---|---|---|---|
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |